¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24
±³À°ÀÏÀÚ : 2024-05-24
±³À°Àå¼Ò : ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ 5Ãþ À̺¥Æ®È¦A+B ¿Ü 1°³·ë

±³À°ÁÖÁ¦ : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇÑ¿µ»óÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ

´ã´çÀÚ : ÁÖÇýÁ¤
¿¬¶ôó : 02-465-9070

À̸ÞÀÏ : office@intervention.or.kr

±³À°Á¾·ù : ¿µ»óÀÇÇаú

Âü¼®¿¹»óÀÎ : 300¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 120,000¿ø  

ºñ°í »çÀüµî·Ï-Á¤È¸¿ø50000¿ø, Àü¹®ÀÇ100000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 30000¿ø, ÁØȸ¿ø¹×±âŸ 50000¿ø/ÇöÀåµî·Ï-Á¤È¸¿ø70000¿ø, Àü¹®ÀÇ120000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 50000¿ø, ÁØȸ¿ø¹×±âŸ 70000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 12:50~13:00 Opening Remarks ()

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:00~13:15 ´ëÇ÷°ü ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ÃÖÅ¿ø(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:15~13:30 º¹ºÎ ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ¼­»óÇö(¿ø±¤ÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:30~13:45 °ñ¹Ý/¿äµµ ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ȲÁ¤ÇÑ(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:45~14:00 ¿Ü»ó¿Ü°úÀÇ°¡ ¹Ù¶óº» ÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐÀÇ ÇöȲ°ú ¿ªÇÒ ¹ÚÂù¿ë(¼­¿ïÀÇ´ë)

ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:00~14:20 Coffee break ()

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:20~14:35 Current status of anticancer agents for cTACE in Korea ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:35~14:50 Idarubicin: an alternative to dox in cTACE ÃÖÁø¿ì(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:50~15:05 Cisplatin-based cTACE ±èÁøÇü(¿ï»êÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:05~15:20 The role of DEB-TACE and bland embolization as alternative to cTACE À̺´Âù(Àü³²ÀÇ´ë)

Åä·Ð 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:20~15:40 Panel discussion: Without Dox powder, what will be the approach for TACE? ()

ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:40~16:00 Coffee break ()

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:00~16:20 Biliary stone removal using balloon catheter, stone basket ±è¼öÈ£, À±Á¾Çõ(°¡Å縯ÀÇ´ë, °í½ÅÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:20~16:40 GB stone removal technical tips, Biliary stone removal using ERCP and SpyGlass ±è¿µÈ¯, ÀÌ»óÈÆ(°è¸íÀÇ´ë, °Ç±¹ÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:40~17:00 Biliary stone: surgical consideration À¯Áø¼ö(¼º±Õ°üÀÇ´ë)

ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 17:00~17:10 Coffee break ()

±âŸ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 17:10~17:20 What¡¯s new ()

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:20~14:32 (±¸¿¬¹ßÇ¥) Evaluation of patients undergoing Thoracic endovascular aortic repair for blunt thoracic aortic injury at a level 1 trauma center: Short term outcomes on left subclavian artery preservation with short proximal landing zones ±è¿ëÈÆ(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:32~14:44 (±¸¿¬¹ßÇ¥) Resorbable, Spherical Gelatin Particles versus Tris-Acryl Gelatin Microspheres for Uterine Artery Embolization: Randomized Controlled Trial ±è¸¸µæ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:44~14:56 (±¸¿¬¹ßÇ¥) The safety and efficacy of preoperative embolization in patients with bladder cancer, above T2 or VI-RADS 3 on CT and MRI: A Propensity Score-Matched Study ÀÌÈ£ÁØ(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:56~15:08 (±¸¿¬¹ßÇ¥) Clinical factors associated with femoral artery pseudoaneurysm after femoral access for interventional procedures ½Åº´±Ç(ÀüºÏÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 15:08~15:20 (±¸¿¬¹ßÇ¥) Ultrasound-Guided Femoral Branch Block for Femoral Arterial Access in Endovascular Aneurysm Repair: A Study on Analgesic Efficacy and Safety Á¶¿µÁ¾(¿ï»êÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 16:00~16:24 Diagnostic imaging of lymphatic disease: MR lymphangiography, CT lymphangiography Çã¼¼¹ü, ½ÅÁöÈÆ(¼­¿ïÀÇ´ë, ¿ï»êÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 16:24~17:00 Treatment of chylothorax, traumatic chylous ascites, pelvic leaks and lymphoceles Çöµ¿È£, ±èÁø¿ì, ±è°æ¹Î(¼º±Õ°üÀÇ´ë, ¾ÆÁÖÀÇ´ë, ¿¬¼¼ÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-05-24
´ÙÀ½±Û Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦ 44 Â÷ KSTH Ãá°èÇмú´ëȸ : 2024-05-24
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 75 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 40 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 48 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 55 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 44 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 45 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 21 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 18 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 46 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 22 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 18 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 47 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 31 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 33 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 28 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷